Product Description: Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis[1][2][3].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Goffe B, et al. Etanercept: An overview. J Am Acad Dermatol. 2003;49(2 Suppl):S105-S111./[2]Goldenberg MM. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther. 1999;21(1):75-2./[3]Totoson P, et al. Etanercept improves endothelial function via pleiotropic effects in rat adjuvant-induced arthritis. Rheumatology (Oxford). 2016;55(7):1308-1317./[4]Haraoui B, et al. Etanercept in the treatment of rheumatoid arthritis. Ther Clin Risk Manag. 2007;3(1):99-105.
CAS Number: 185243-69-0
Molecular Weight: 150000 (Average)
Compound Purity: 99.20
Research Area: Inflammation/Immunology; Cancer
Solubility: H2O
Target: Bacterial;TNF Receptor